Skip to main content

Table 4 Adjusting effects for possible confounders - SVR, HIV-positive patients

From: The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals

  SVR No SVR Uni-variate Multi-variate Multivariate
  n = 64 n = 54 p-value p-value Odds-ratio (95% CI)
Age [years] 40 (27 - 54) 41 (27 - 48) 0.566 - -
Male sex [%] 75 78 0.662 - -
Transm. risk IVDU [%] 20 30 0.709 - -
HCV GT 1 or 4 [%] 50 76 0.002 0.001 0.2 (0.1 - 0.5)
HCVRNA ≥ 5 × 105 IU/ml[%] 42 63 0.014 0.009 0.3 (0.1 - 0.7)
ALT [IU/l] 63 (19 - 190) 80 (25 - 250) 0.368 - -
Weight adapted RBV [%] 88 73 0.237 - -
Tx duration 48 wks [%] 47 27 0.309 - -
Enrollment period [%]
    2002 - 2004 56 67 0.253 - -
    2005 - 2007 44 32    
Treatment arm [%]
    B (no HAART) 44 39    
    C1 (NRTI-cont.) 33 52 0.047 0.025 0.3 (0.1 - 0.9)*
    C2 (NRTI free) 23 9    
HIV-RNA [copies/ml, log 10 ] 1.7 (1.7 - 4.8) 1.7 (1.7 - 4.8) 0.372 -  
CD4-cellcount      
    [/μl] 487 (236 - 1042) 542 (222 - 831) 0.828 -  
    [%] 27 (15 - 41) 26 (12 - 41) 0.364 -  
Anemia [%]
    Grade 1/2 11 11 1.000 .  
    Grade 3/4 - -    
Leucopenia [%]
    Grade 1/2 47 41 0.578 -  
    Grade 3/4 9 7 0.753   
Thrombocytopenia [%]
    Grade 1/2 47 43 0.712 -  
    Grade 3/4 5 6 1.000   
Clinical adverse events [%]
    Grade 1/2 67 69 1.000 -  
    Grade 3/4 11 13 0.781   
Dose reduction PegIFN [%] 11 9 1.000   
Dose reduction RBV [%] 13 20 0.215 -  
Treatm. discont. AEs [%] 5 24 0.003 0.004 0.1 (0 - 0.5)
  1. Data shown as percent of patientsor median (95% range); *treatment arm C1 compared to B and C2 (reference) SVR sustained virological response, IVDU intravenous drug abuse, GT HCV genotype; ALT serum alanine aminotransferase, RBV ribavirin, Tx Treatment, wks weeks, NRTI nucleos(t)ide reverse transcriptase inhibitor, Treatment discont. AEs Treatment discontinuation due to adverse events.